New radioactive drug takes aim at Hard-to-Treat prostate cancer

NCT ID NCT06229366

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called [Ac-225]-PSMA-62 in people with prostate cancer that has spread to other parts of the body. The drug delivers a small amount of radiation directly to cancer cells. The main goals are to find the safest dose and to see if it can shrink tumors or slow the disease. About 142 adults with either hormone-sensitive or castration-resistant prostate cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma male reproductive organ cancer metastatic prostate carcinoma prostate cancer prostate carcinoma Urogenital Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • BC Cancer Vancouver

    Vancouver, V5Z4E6, Canada

  • Centre Hospitalier Universite de QUEBEC

    Québec, G1J 1Z4, Canada

  • Hopital De Chicoutimi

    Saguenay, G7H 5H6, Canada

  • Jewish General Hospital

    Montreal, H3T 1E2, Canada

  • Juravinski

    Hamilton, L8V 5C2, Canada

  • McGill University

    Montreal, H4A 3J1, Canada

  • Princess Margaret Cancer Centre

    Toronto, M5G 2M9, Canada